SG11202001749SA - Methods of using dantrolene to treat nerve agent exposure - Google Patents
Methods of using dantrolene to treat nerve agent exposureInfo
- Publication number
- SG11202001749SA SG11202001749SA SG11202001749SA SG11202001749SA SG11202001749SA SG 11202001749S A SG11202001749S A SG 11202001749SA SG 11202001749S A SG11202001749S A SG 11202001749SA SG 11202001749S A SG11202001749S A SG 11202001749SA SG 11202001749S A SG11202001749S A SG 11202001749SA
- Authority
- SG
- Singapore
- Prior art keywords
- dantrolene
- methods
- nerve agent
- agent exposure
- treat nerve
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762554049P | 2017-09-05 | 2017-09-05 | |
| US201862674406P | 2018-05-21 | 2018-05-21 | |
| PCT/US2018/049515 WO2019050923A1 (en) | 2017-09-05 | 2018-09-05 | METHODS OF USING DANTROLENE TO TREAT EXPOSURE TO A NEUROTOXIC AGENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001749SA true SG11202001749SA (en) | 2020-03-30 |
Family
ID=63708449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001749SA SG11202001749SA (en) | 2017-09-05 | 2018-09-05 | Methods of using dantrolene to treat nerve agent exposure |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200383954A1 (https=) |
| EP (1) | EP3678659B1 (https=) |
| JP (2) | JP2020532555A (https=) |
| KR (1) | KR20200047655A (https=) |
| CN (1) | CN111093652A (https=) |
| AU (1) | AU2018328131B2 (https=) |
| BR (1) | BR112020004429A2 (https=) |
| CA (1) | CA3074732A1 (https=) |
| IL (1) | IL272847B1 (https=) |
| MA (1) | MA50080A (https=) |
| MX (2) | MX2020002485A (https=) |
| SG (1) | SG11202001749SA (https=) |
| UA (1) | UA126688C2 (https=) |
| WO (1) | WO2019050923A1 (https=) |
| ZA (1) | ZA202001258B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022538608A (ja) * | 2019-06-28 | 2022-09-05 | ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア | アルツハイマー病の治療のための鼻腔内ダントロレン投与 |
| WO2023081873A1 (en) * | 2021-11-05 | 2023-05-11 | Quorum Innovations, Llc | Materials and methods for preventing or reducing toxicity to organophosphates and other toxic materials |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7758890B2 (en) * | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| EP1603513B1 (en) * | 2003-03-04 | 2020-12-30 | Lyotropic Therapeutics, Inc. | Dantrolene compositions |
| WO2013040501A1 (en) * | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
| DK2925327T3 (da) * | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
-
2018
- 2018-09-05 UA UAA202002205A patent/UA126688C2/uk unknown
- 2018-09-05 BR BR112020004429-6A patent/BR112020004429A2/pt unknown
- 2018-09-05 JP JP2020512813A patent/JP2020532555A/ja active Pending
- 2018-09-05 MX MX2020002485A patent/MX2020002485A/es unknown
- 2018-09-05 US US16/644,281 patent/US20200383954A1/en not_active Abandoned
- 2018-09-05 WO PCT/US2018/049515 patent/WO2019050923A1/en not_active Ceased
- 2018-09-05 MA MA050080A patent/MA50080A/fr unknown
- 2018-09-05 KR KR1020207009450A patent/KR20200047655A/ko not_active Ceased
- 2018-09-05 EP EP18779490.4A patent/EP3678659B1/en active Active
- 2018-09-05 CA CA3074732A patent/CA3074732A1/en active Pending
- 2018-09-05 CN CN201880057290.XA patent/CN111093652A/zh active Pending
- 2018-09-05 AU AU2018328131A patent/AU2018328131B2/en active Active
- 2018-09-05 SG SG11202001749SA patent/SG11202001749SA/en unknown
-
2020
- 2020-02-23 IL IL272847A patent/IL272847B1/en unknown
- 2020-02-27 ZA ZA2020/01258A patent/ZA202001258B/en unknown
- 2020-03-04 MX MX2023012415A patent/MX2023012415A/es unknown
-
2021
- 2021-12-02 US US17/540,878 patent/US20220087980A1/en active Pending
-
2023
- 2023-01-27 JP JP2023010846A patent/JP2023055802A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023055802A (ja) | 2023-04-18 |
| EP3678659C0 (en) | 2025-12-17 |
| MX2020002485A (es) | 2020-07-20 |
| BR112020004429A2 (pt) | 2020-10-20 |
| RU2020112318A (ru) | 2021-10-06 |
| NZ762056A (en) | 2025-10-31 |
| JP2020532555A (ja) | 2020-11-12 |
| AU2018328131B2 (en) | 2024-04-18 |
| US20200383954A1 (en) | 2020-12-10 |
| EP3678659A1 (en) | 2020-07-15 |
| UA126688C2 (uk) | 2023-01-11 |
| MA50080A (fr) | 2020-07-15 |
| IL272847B1 (en) | 2026-03-01 |
| MX2023012415A (es) | 2023-11-01 |
| CA3074732A1 (en) | 2019-03-14 |
| US20220087980A1 (en) | 2022-03-24 |
| AU2018328131A1 (en) | 2020-03-12 |
| ZA202001258B (en) | 2023-10-25 |
| RU2020112318A3 (https=) | 2021-10-26 |
| EP3678659B1 (en) | 2025-12-17 |
| CN111093652A (zh) | 2020-05-01 |
| IL272847A (en) | 2020-04-30 |
| WO2019050923A1 (en) | 2019-03-14 |
| KR20200047655A (ko) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006746B (en) | Methods of treatment | |
| SG11201912759RA (en) | Methods and compositions for treatment of concrete wash water | |
| IL251066A0 (en) | Preparations and methods for the treatment of metabolic disorders | |
| IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| IL249793A0 (en) | Preparations and methods of use for the treatment of metabolic disorders | |
| SG10202010009XA (en) | Methods and compositions for treatment of concrete wash water | |
| IL253197A0 (en) | Methods for the treatment of sphingosine-1-phosphate receptor 1-related conditions | |
| ZA201703904B (en) | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer | |
| IL254568A0 (en) | Compounds and forms for the treatment of female sexual disorders | |
| IL254842B (en) | Therapeutic preparations and methods for use in cancer treatment | |
| PL3157531T3 (pl) | Sposoby i kompozycje do stymulacji jelitowego układu enteroendokrynnego w leczeniu chorób lub stanów związanych z tym układem | |
| IL265830A (en) | Compounds and preparations for the treatment of leishmaniasis, methods of diagnosis and treatment by their use | |
| LT3661510T (lt) | Elgesio pakitimų gydymo būdai | |
| EP3253211A4 (en) | Compositions and methods for treatment of edema | |
| IL253847A0 (en) | Methods of treating diseases | |
| IL272847A (en) | Methods of using dantrolene to treat exposure to nerve gas | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| IL252070A0 (en) | Preparations containing apoequrin and methods of using them to treat neuritis | |
| HK40031037A (en) | Methods of using dantrolene to treat nerve agent exposure | |
| ZA201908495B (en) | Methods of treating symptoms of gastroparesis using velusetrag | |
| ZA201805402B (en) | Treatment of contaminated water | |
| PT3661510T (pt) | Métodos de tratamento de alterações do comportamento |